ASTS
AST SpaceMobile, Inc.
ASTS trails on the overall score without a compensating advantage in the available component scores.
GEN
Gen Digital Inc.
GEN has the edge over ASTS overall, supported by lower modeled downside and stronger fundamentals.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
GEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Stable |
GEN's profitability and cash flow are currently strong, and its revenue and balance sheet are stable.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
GEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.3x | $16.34 | -45% |
| Forward | 9.5x | $29.69 | — |
| Current | 15x | $29.69 | — |
| Fair | 18x | $35.76 | +20% |
| Expensive | 28x | $54.70 | +84% |
Historical ranges are pointers, not guarantees.
GEN's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 9.5x next year's earnings.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
GEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for GEN, with profitability improving.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
GEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.12 | +58% |
| Q3 2026 | $1.98 | +118% |
| Q2 2026 | $1.71 | +78% |
| Q1 2026 | $1.57 | +52% |
| Q4 2025 | $0.96 | -6.8% |
| Q3 2025 | $0.91 | -8.1% |
| Q2 2025 | $0.96 | 0% |
| Q1 2025 | $1.03 | +7.3% |
| Q4 2024 | $1.03 | -53% |
GEN has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS's revenue has grown year over year for 11 quarters in a row: $42M last quarter, up 187% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
GEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +12% |
| Q2 2026 | $1.3B | +6.3% |
| Q1 2026 | $1.3B | +27% |
| Q4 2025 | $1.2B | +26% |
| Q3 2025 | $1.2B | +25% |
| Q2 2025 | $1.3B | +30% |
| Q1 2025 | $1B | +4.4% |
| Q4 2024 | $986M | +3.7% |
GEN's revenue has grown year over year every quarter since early 2021: $1.4B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | +1.1 points |
| Q2 2026 | 33% | -2.3 points |
| Q1 2026 | 63% | +21 points |
| Q4 2025 | 35% | -3 points |
| Q3 2025 | 36% | -5.4 points |
| Q2 2025 | 35% | -7.7 points |
| Q1 2025 | 41% | -0.1 points |
| Q4 2024 | 38% | +2.7 points |
GEN has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
GEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $323M | +202% |
| Q2 2026 | $430M | +6.2% |
| Q1 2026 | $476M | +1.3% |
| Q4 2025 | $535M | +68% |
| Q3 2025 | $107M | -31% |
| Q2 2025 | $405M | +55% |
| Q1 2025 | $470M | -66% |
| Q4 2024 | $318M | +3.6% |
GEN has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
GEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -3.4% | -21M shares |
| 3 years | -6.4% | -41M shares |
| 5 years | +2% | +12M shares |
| Available history | -6.8% | -44M shares |
GEN has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $171M |
| Q2 2026 | $100M |
| Q1 2026 | $200M |
| Q4 2025 | $300M |
| Q3 2025 | — |
| Q2 2025 | $134M |
| Q1 2025 | — |
| Q4 2024 | — |
GEN spent $771M buying back its own shares over the past year, about six times what it spent the year before.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.9x | Moderate |
| Q2 2026 | 3.0x | Moderate |
| Q1 2026 | 3.0x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 3.9x | Elevated |
| Q2 2025 | 4.1x | High |
| Q1 2025 | 3.6x | Elevated |
| Q4 2024 | 3.8x | Elevated |
GEN's net debt is about 2.9 years of its operating earnings (EBITDA), down from 3.9 years a year ago.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
GEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 81.3 | Overbought |
GEN's weekly RSI is 59 (neutral) and its Stochastic is 81 (overbought).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
GEN PE vs Technology Sector
| Metric | GEN | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 28x | 46% below |
| PE % | 32 | 35 | 3 pts below |
GEN is trading at 15x earnings, a 46% discount to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
GEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.6 | 16% above |
| 20 week MA | $27.2 | 9% above |
| 50 week MA | $25.0 | 19% above |
| 100 week MA | $26.4 | 12% above |
| 200 week MA | $24.2 | 23% above |
GEN has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
GEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.6 | $21.0 | -18% |
| 2021 | $21.0 | $25.9 | +23% |
| 2022 | $25.9 | $21.3 | -18% |
| 2023 | $21.3 | $22.8 | +7.1% |
| 2024 | $22.8 | $27.7 | +21% |
| 2025 | $27.7 | $27.8 | +0.4% |
| 2026 YTD | $27.8 | $29.7 | +6.9% |
GEN has the edge over ASTS on returns for 2026, with the stronger performance.